Amgen

AMGN NASDAQ
177.47
+1.35
+0.77%
After Hours: 177.47 0 0.00% 16:59 07/16 EDT
Open
176.34
Prev Close
176.12
High
177.77
Low
175.91
Volume
2.26M
Avg Vol (3M)
2.95M
52 Week High
210.19
52 Week Low
166.30
% Turnover
0.37%
Market Cap
108.25B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Amgen AMGN stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
MORE >

Recently

Name
Price
%Change